WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM

Similar documents
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

HIV Drugs and the HIV Lifecycle

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

HIV medications HIV medication and schedule plan

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care

Antiretroviral Dosing in Renal Impairment

HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:


Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications

Antiretrovial Crushable/Liquid Formulation Chart

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

ANTIRETROVIRAL TREATMENTS (Part 1of

ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

Nobel /03/28. HIV virus and infected CD4+ T cells

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920

HIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop

Nothing to disclose.

ADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

A Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs

BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search

Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection

Appropriate Use & Safety Edits

HIV Infection & AIDS in Low- and Middle-Income Countries

JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet

Adherence Strategies for Older Adults. AIDS Community Research Initiative of America (ACRIA)

Addressing Pediatric Needs of the Most Neglected: next steps

FORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary

Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.

Drug Treatment Program Update

Approach for the Newly Diagnosed HIV Positive Patient

Genotyping and Drug Resistance in Clinical Practice. Case Studies

Index. Nurs Clin N Am 40 (2005) Note: Page numbers of article titles are in boldface type.

Lipodystrophy Demographic and Health History Questionnaire (ART)

FLORIDA!A MEDICAID' Better Health Care for all Floridians. May

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012

continuing education for pharmacists

Antiretroviral Pregnancy Registry

MEDICATION RELATED ISSUES IN THE HIV PATIENT. LEONARD SOWAH, MBChB, MPH, FACP

October 26-28: Training Day 1

The ART of Antiretroviral Therapy in Critically-ill Patients with HIV

World AIDS Day Year-by-Year Milestones in HIV/AIDS. healthlibrary

treatment passport 1

NON-OCCUPATIONAL POST EXPOSURE PREVENTION. when you think you were exposed to hiv within the past three days

P.I. Perspective. December 2008, Issue #47. Information, Inspiration and Advocacy for People Living with HIV/AIDS

Simplifying HIV Treatment Now and in the Future

INDEX. indications...11 initiation of metabolic and morphologic complications

HIV in the Workplace

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

HIV Management Update 2015

30 Years of HIV: An Update on Treatment Guidelines and Beyond

PROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY

Industry Data Request

The New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine

Human Immunodeficiency Virus Infection A Modern Day Epidemic

Objectives. HIV Treatment in Recently In 1996 the introduction of protease inhibitors decreasing the death rate of those infected by 50%.

Industry Request Integrase Inhibitors

Matters of the HAART: An Update on Current Treatment Options for HIV

New Frontiers for Treatment Strategies for HIV Care

Human Immunodeficiency Virus (HIV)

Outline Epidemiology: Global and U.S. How are we doing in terms of goals of treatment? Updates in the fast moving field of HIV medicine EPIDEMIOLOGY

Medication Errors Focus on the HIV-Infected Patient

Midwestern Underwriting Conference 2016

Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course

HIV Today: Examining the Latest Treatment Advances, Barriers to Care, and Pharmacists Implications

OB/GYN CHART REVIEW DRAFT: NOT FOR DISTRTIBUTION

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist

HIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine

Overview of HIV. LTC Paige Waterman

HIV and YOU. Special 2008 Update!

May 2016 P & T Updates

Division of Public Health Services Office of the Assistant Director Public Health Preparedness Services

Fundamentals of Antiretroviral Therapy

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

HIV in the United States: At A Glance

Recreational Drugs and HIV Antiretrovirals. A Guide to Interactions for Clinicians

ART and Prevention: What do we know?

Principles of HIV Drug Resistance: Resistance to New Drug Classes. Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada

P.I. Perspective. To nuke, or not to nuke? April 2007, Issue #43. Information, Inspiration and Advocacy for People Living with HIV/AIDS CONTENTS

HIV Update: Looking Forward, Where are we going? Outline

The ART of Managing Drug-Drug Interactions in Patients with HIV

The Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018

Selecting an Initial Antiretroviral Therapy (ART) Regimen

Overview of HIV. Christina Polyak, MD, MPH. Research Physician. U.S. Military HIV Research Program, Walter Reed Army Institute of Research

Criteria for Oral PrEP

Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course

Jonathan Cohn MD Wayne State University July 24,

Blood-Borne Pathogens and Post-Exposure Prophylaxis

The ABCs of ART: Designing Initial Antiretroviral Regimens for Beginners

The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project. ARV Dosing in End Stage Renal Disease

NATAPNATIONAL. HIV 102: Care & Treatment AIDS TREATMENT ADVOCACY PROJECT. Origins of HIV. Table of Contents. National AIDS Treatment Advocacy Project

HIV / AIDS & Opportunistic Infections.

Transcription:

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take insulin (either by injection or inhaler) OR take any of the following oral medications: a thiazolidinedione [including pioglitazone (Actos) or rosiglitazone (Avandia)] OR metformin (Glucophage) for diabetes, or to help control your blood sugar? YES... 1 NO... 2 A3. Do you currently take any other prescribed medications for diabetes or to lower your blood sugar? YES... 1 NO... 2 (A6) A4. Do these include any of the following? YES NO i. DATE LAST TAKEN ii. TIME LAST TAKEN a. Acarbose (Precose)... 1 2 (b) / / : b. Chlorpropamide (Diabinese)... 1 2 (c) / / : c. Glimepiride (Amaryl)... 1 2 (d) / / : d. Glipizide (Glucotrol)... 1 2 (e) / / : e. Glyburide (Micronase, Diabeta) 1 2 (g) / / : g. Miglitol (Glyset)... 1 2 (h) / / : h. Orlistat (Xenical)... 1 2 (j) / / : j. Repaglinide (Prandin)... 1 2 (l) / / : l. Nateglinide (Starlix)... 1 2 (m) / / : m. Other SPECIFY: 1 2 (A5) / / : iii. AM/PM INDICATOR Page 1 of 6

A5. IN THE LAST EIGHT (8) HOURS, HAS PARTICIPANT TAKEN ANY OF THE MEDICATIONS LISTED IN QUESTIONS A4a A4l? YES... 1 (PROMPT, BELOW) NO... 2 PROMPT: IF PARTICIPANT HAS TAKEN ANY OF THE DIABETES MEDICATIONS LISTED IN QUESTIONS A4a A4l IN THE LAST EIGHT (8) HOURS (A5 = 1), SHE MAY NOT PARTICIPATE IN THE GLUCOSE TOLERANCE TEST (GTT) AT THIS TIME. PLEASE RESCHEDULE THE PARTICIPANT FOR A GLUCOSE TOLERANCE TEST AND COMPLETE A NEW MS01 AT THAT TIME. A6a. HAND PARTICIPANT ANTIVIRAL PHOTO MEDICATION CARDS. GO THROUGH CARDS WITH PARTICIPANT, SAYING THE NAME OF EACH DRUG ALOUD AND ASKING HER TO TELL YOU YES OR NO WHETHER SHE HAS TAKEN THIS DRUG IN THE LAST 3 DAYS. CHECK BELOW NEXT TO EACH DRUG PARTICIPANT REPORTS HAVING TAKEN. FOR DRUGS NOT LISTED, CHECK OTHER ANTI-VIRAL, RECORD NAME AS STATED BY PARTICIPANT AND FILL IN CORRESPONDING 3-DIGIT DRUG CODE FROM DRUG LIST 1. I m going to ask about any antiretroviral medications you may have taken in the last 3 days. In addition to all your prescribed medications, please include any antiretroviral medications you have taken as part of a research study, including those in which you may have been blinded to the study medication. In the last 3 days, have you taken Combination Medications Non-Nucleoside RTIs 262 Atripla (Sustiva + Viread + Emtriva) 255 Intelence (etravirine, TMC 125) 227 Combivir (AZT + 3TC) 194 Rescriptor (delavirdine) 254 Epzicom (Ziagen + Epivir) 220 Sustiva (efavirenz) 240 Trizivir (abacavir + AZT + 3TC) 191 Viramune (nevirapine) 253 Truvada (Viread + Emtriva) 276 Edurant (rilpivirine, TMC 278) 280 Complera (FTC + RPV + TDF) 287 Stribild (FTC + Viread + EVG + cobicistat) Protease Inhibitors Entry Inhibitors 238 Aptivus (tipranavir) 233 Fuzeon (T-20, enfuvirtide) 212 Crixivan (indinavir) 265 Selzentry (maraviroc) 210 Invirase (saquinavir) Nucleoside/Nucleotide RTIs 217 Kaletra (lopinavir + ritonavir) 239 Emtriva (emtricitabine, FTC) 249 Lexiva (fosamprenavir) 204 Epivir (lamivudine, 3-TC) 211 Norvir (ritonavir) 092 Retrovir (AZT, zidovudine, ZDV) 256 Prezista (TMC-114, darunavir) 147 Videx / Videx EC (didanosine, ddi) 243 Reyataz (atazanavir) 234 Viread (tenofovir) 216 Viracept (nelfinavir) 159 Zerit (stavudine, d4t) 218 Ziagen (abacavir) Other 207 Droxia or Hydrea (hydroxyurea) Integrase Inhibitors Other anti-viral(s) (from Drug List 1) 264 Isentress (raltegravir, MK 0518) Specify name of other antiviral: Specify name of other antiviral: Drug Code: Drug Code: b. ENTER THE TOTAL NUMBER OF MEDICATIONS THE PARTICIPANT REPORTED TAKING IN QUESTION A6a: PROMPT: IF QUESTION A6b = 0, SKIP TO QUESTION A8. Page 2 of 6

A7. FOR EACH MEDICATION LISTED IN QUESTION A6a, ASK PARTICIPANT THE DATE AND TIME SHE LAST TOOK THAT MEDICATION AND COMPLETE COLUMNS a, b, c AND d. i. ii. iii. iv. v. vi. START MS01s1 a. DRUG CODE b. DATE LAST TAKEN c. TIME LAST TAKEN d. AM/PM INDICATOR END MS01s1 A8. When was the last date and time you had anything to eat or drink, other than water? a. DATE: / / M D Y b. TIME: : AM... 1 A9. Did you take any other medications in the last three days? This could include prescription medications not named above, over the counter (non-prescription) medications, and/or alternative or complementary medications, like herbs or vitamins. YES... 1 NO... 2 (SECTION B) Page 3 of 6

A10. ASK PARTICIPANT TO LIST ALL MEDICATIONS SHE HAS TAKEN IN THE LAST THREE DAYS, AND THE DATE AND TIME SHE LAST TOOK EACH MEDICATION. COMPLETE COLUMNS a, b, c AND d. START MS01s2 a. DRUG NAME b. DATE LAST TAKEN c. TIME LAST TAKEN d. AM/PM INDICATOR i. ii. iii. iv. v. vi. END MS01s2 A10e. ENTER THE TOTAL NUMBER OF MEDICATIONS THE PARTICIPANT REPORTED TAKING IN QUESTION A10a: SECTION B. FIRST BLOOD DRAW (FASTING) B1. TIME OF FIRST BLOOD DRAW: : AM... 1 B2. PHLEBOTOMIST'S INITIALS B3. GLUCOSE Gray Top 2 ml 1 2 (i) 1 (B4) 2 mls. B4. INSULIN Red-Top (SST) 4 ml 1 2 (i) 1 (PROMPT) 2 mls. PROMPT: IF QUESTION A2 = 1, SKIP TO PROMPT AT END OF FORM. OTHERWISE, PLEASE HAVE PATIENT DRINK 75G GLUCOSE LOAD WITHIN 5 MINUTES AND CONTINUE WITH SPECIMEN DRAW. Page 4 of 6

B6. DID THE PARTICIPANT FULLY DRINK GLUCOSE (75G GLUCOSE LOAD)? YES... 1 (B6a) NO... 2 SPECIFY REASON: (END FORM) a. TIME GLUCOSE LOAD ADMINISTERED: : AM... 1 PM... 2 SECTION C. SECOND BLOOD DRAW (30 MINUTES) C1. TIME OF SECOND BLOOD DRAW: : AM... 1 C2. PHLEBOTOMIST'S INITIALS C3. GLUCOSE Gray Top 2 ml 1 2 (i) 1 (C4) 2 mls. C4. INSULIN Red-Top (SST) 4 ml 1 2 (i) 1 (D1) 2 mls. SECTION D. THIRD BLOOD DRAW (60 MINUTES) D1. TIME OF THIRD BLOOD DRAW: : AM... 1 D2. PHLEBOTOMIST'S INITIALS D3. GLUCOSE Gray Top 2 ml 1 2 (i) 1 (E1) 2 mls. Page 5 of 6

SECTION E. FOURTH BLOOD DRAW (120 MINUTES) E1. TIME OF FOURTH BLOOD DRAW: : AM... 1 E2. PHLEBOTOMIST'S INITIALS E3. GLUCOSE Gray Top 2 ml 1 2 (i) 1 (E4) 2 mls. E4. INSULIN Red-Top (SST) 4 ml 1 2 (i) 1 (END) 2 mls. PROMPT: AFTER PROCESSING, SAMPLES FOR INSULIN AND GLUCOSE WILL BE BATCHED AND THEN SHIPPED TO QUEST DIAGNOSTICS. SEE THE WIHS MANUAL OF OPERATIONS, SECTION 25, FOR INSTRUCTIONS ON PROCESSING AND SHIPPING. Page 6 of 6